An experimental research of magnetic resonance tumor targeting imaging with Gd labeled human telomerase reverse transcriptase antisense oligonucleotide (Gd-DOTA-hTERT ASON)
|更新时间:2025-12-31
|
An experimental research of magnetic resonance tumor targeting imaging with Gd labeled human telomerase reverse transcriptase antisense oligonucleotide (Gd-DOTA-hTERT ASON)
China OncologyVol. 23, Issue 10, Pages: 821-828(2013)
朱高红, 任炳秀, 卫江亮, et al. An experimental research of magnetic resonance tumor targeting imaging with Gd labeled human telomerase reverse transcriptase antisense oligonucleotide (Gd-DOTA-hTERT ASON)[J]. China Oncology, 2013, 23(10): 821-828.
朱高红, 任炳秀, 卫江亮, et al. An experimental research of magnetic resonance tumor targeting imaging with Gd labeled human telomerase reverse transcriptase antisense oligonucleotide (Gd-DOTA-hTERT ASON)[J]. China Oncology, 2013, 23(10): 821-828. DOI: 10.3969/j.issn.1007-3969.2013.10.007.
An experimental research of magnetic resonance tumor targeting imaging with Gd labeled human telomerase reverse transcriptase antisense oligonucleotide (Gd-DOTA-hTERT ASON)
Tc标记的DOTA-hTERTASON生物分布实验;建立人黑色素瘤A375裸鼠模型,分别于腹腔注射前及注射后0.5、1、2、4、6、24 h在7.0T Magnetic Resonance Imaging(MRI)下行T1WI显像,以肿瘤及其周围正常组织作为感兴趣区(region of interest,ROI)计算信噪比(signal to noise ratio,SNR)并与Gd-DTPA进行比较;显像后48 h处死小鼠,以免疫组织化学方法检测肿瘤组织端粒酶活性。结果:Gd-DOTA-hTERT ASON的标记率约为65%,在37 ℃新鲜人血清中温育24 h后,探针的降解率低于3%;A375细胞对探针的摄取约为8.5%,Gd-DOTA-hTERT ASON转染的A375细胞信号强度明显高于Gd-DTPA和DOTA-hTERT ASON组;肿瘤在注射反义探针和Gd-DTPA均表现为明显强化,反义探针组SNR最高可达2.37,最大强化时间为注射后2~6 h,且可被DOTA-hTERT ASON所抑制(P<0.05),而Gd-DTPA组强化时间为注射后2 h;Gd-DOTA-hTERT ASON可抑制肿瘤端粒酶活性。结论:Gd-DOTA-hTERT ASON显示了良好的肿瘤靶向性,对端粒酶阳性表达的肿瘤具有潜在的定性诊断价值。
Abstract
[Abstract] Background and purpose: Researches had indicated that about over 85% of malignant tumors highly express telomerase activity. So t
elomerase has become one of the important methods in the research field of tumor diagnosis and treatment. Nowadays
several reports about malignant tumor which over expresses hTERT targeting imaging with radionuclide labeled hTERT ASON had been published. In these reports
high quality of pictures can hardly be acquired because of poor anatomical and spacial resolution in nuclear imaging itself. Accordingly
in this study
we developed a method of detecting human telomerase in vivo with magnetic resonance imaging (MRI) and evaluate its feasibility. Methods: Firstly
Uniformly phosphorothioate-modified human telomerase reverse transcriptase antisense oligonucleotide (hTERT ASON) was labeled with Gd
3+
through the bifunctional chelator 1
4
7
10-tetraazacyclododecane-N
N’
N’’
N’’’-tetraacetic acid (DOTA) and iv vitro experiments were performed to characterize the antisense probes (for biodistribution and cellular uptake
99m
Tc-DOTA-ASON was used in stead of Gd- DOTA-ASON). Then Gd-DOTA-ASON was injected intraperitoneally in pulmonary adenocarcinoma A375 nude mice tumor-bearing BALB/c for in vivo imaging using 7.0 T Micro MRI periodically
tumors and their surrounding tissues were defined as region of interest (ROI) to calculate the signal to noise ratio (SNR) of tumor to muscle using Gd-DTPA as control. Finally
immunohistochemical analysis of telomerase activity of each xenograft was operated 2 days after imaging. Results: The binding efficiency of Gd-DOTA-ASON reached was as high as 65% (63.2±2.4
n=6). And it can maintain 61% in fresh human serum and normal saline at 37 ℃ over 24 h; A375 cells showed an uptake of 8.5% when incubated with 99mTc -DOTA-ASON; In comparing with DOTA-ASON and Gd-DTPA
cells transected with Gd-DOTA-ASON had higher SI when performed MRI with T1WI. The hTERT-expressing xenografts were obviously enhanced by Gd-DOTA-ASON at 0.5–6 h after injection and the SNR can reach 2.37
whereas obvious enhancement only could be found within 2 h after injection of Gd-DTPA. Both
labeled and non-labeled antisense probes can suppress the activity of telomerase of A375 cells either in vitro or in vitro. Conclusion: Our research offers proof that Gd-DOTAASON can be used as tumor specific targeting MR probe for diagnosing malignant tumors with high expression of telomerase.